Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer
management. Nonetheless, not all patients benefit from such therapies because they fail to …

Immunotherapy has made significant strides in cancer treatment, particularly through
immune checkpoint blockade (ICB), which has shown notable clinical benefits across …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Chronic lymphocytic leukemia (CLL) has a complex pattern of driver mutations and much of
its clinical diversity remains unexplained. We devised a method for simultaneous subgroup …

B-cell receptor (BCR) signaling is crucial for chronic lymphocytic leukemia (CLL) biology.
IGLV3-21–expressing B cells may acquire a single point mutation (R110) that triggers …

Abstract Background Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with
relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome …

Chronic lymphocytic leukemia (CLL) major stereotyped subset 2 (IGHV3-21/IGLV3-21,∼
2.5% of all cases of CLL) is an aggressive disease variant, irrespective of the somatic …

Lymphoid neoplasms represent a heterogeneous group of disease entities and subtypes
with markedly different molecular and clinical features. Beyond genetic alterations, lymphoid …

Careful histopathologic examination remains the cornerstone in the diagnosis of the
clinically and biologically heterogeneous group of lymphoid malignancies. However, recent …

Hepatocellular cancer is the sixth most frequently diagnosed malignant disease worldwide,
and was responsible for tens of millions of deaths in 2020; however, treatment options for …